Delivery Order SPE2DB20D1047-SPE2DB25FF81G
Award Date 9/4/25
Potential Completion Date 9/5/25
Potential Value $120K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order represents a non-competitive set-aside award and is being performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B virus infection in adults 18...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $134,719.00 on August 27, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- The U.S. Defense Logistics Agency awarded a delivery order valued at $14,637.70 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price delivery order was issued without a set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention...
- The Defense Logistics Agency (DLA) awarded a $273,806 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with completion expected by September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing...
- The Defense Logistics Agency awarded a $139,894.18 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.15 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 ml syringes on August 7, 2025, with completion expected by August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for use in adult populations, representing part...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes valued at $2,106.20. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 27, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 11, 2025, with completion expected by September 12, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and will be performed at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and older,...